CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study. The Adult Lymphoma Treatment Study Group (ALTSG)

We conducted a multi-institutional collaborative study to examine the usefulness and safety of third-generation chemotherapy CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) combined with granulocyte colony-stimulating factor (G-CSF) in the treatment of aggressive non-Hodgkin's lymphoma (NHL). Subjects included patients with aggressive NHL who were 60 yr of age or younger and had been diagnosed as having a low-intermediate, high-intermediate, or high risk using the International Prognostic Index (IPI). A total of 24 patients were enrolled in the study between May 1997 and March 1998, including 9 low-intermediate-risk cases, 13 high-intermediate-risk cases and 2 high-risk cases. Although all 24 patients were originally enrolled in the study, one adult T-cell leukemia/lymphoma case was subsequently excluded. Thus, in the end, 23 cases were evaluated. Evaluation of the efficacy of therapy revealed complete remission in 20 patients (87%). Of these 20 patients, 8 were low-intermediate-risk cases (89%) and 12 were either high-intermediate- or high-risk cases (86%). Partial remission was achieved in 2 patients (8.7%). The 2-yr survival rate was 91.3%, and the 2-yr disease-free survival rate was 81.8%. Grade 3 or higher adverse reactions were granulocytopenia (87%), thrombocytopenia (17.4%) and liver dysfunction (4.3%). CyclOBEAP therapy has been associated with a high remission rate for aggressive NHL. When combined with G-CSF, a high relative dose intensity was maintained for each drug administered (0.94-0.97). Furthermore, although the observation period was short, both the survival rate and disease-free survival rate were good. Hence, we concluded that there were no problems associated with the procedure in terms of safety.     

哮喘致死患者肺组织EG1和EG2的检测及分析

目的　为了研究哮喘发作致死患者肺组织嗜酸性粒细胞浸润情况。方法　研究分成 3组 ,A组为死于哮喘发作 ,B组有哮喘病史但死于非哮喘发作 ,C组无哮喘病史。应用免疫组化技术 ,检测不同死因肺组织单克隆抗体EG1 和EG2 的阳性细胞。结果　 ( 1)哮喘发作致死组的肺组织EG1 和EG2 的阳性细胞明显高于其他两组 ,而哮喘患者非哮喘发作致死组的肺组织EG1 和EG2 的阳性细胞与无哮喘病史组比较无显著差异。 ( 2 )在哮喘发作致死组的支气管与肺实质EG1 阳性细胞数无明显差异 ,但在肺实质的EG2 的阳性细胞明显高于较大的支气管。结论　在哮喘发作致死患者气道和肺组织有大量的嗜酸性粒细胞浸润 ,且以小支气管与肺实质浸润为主     

rhG-CSF动员的人外周血与骨髓不同比例混合对移植物免疫特性的影响

目的探讨rhG-CSF动员的外周血采集物(G-PB)和骨髓(G-BM)不同比例混合对移植物免疫学特性的影响。方法用流式细胞仪测定G-PB和G-BM中T细胞亚群、树突状细胞(DC)亚群的数量,据有核细胞数将G-PB/G-BM按2∶11、∶11、∶2混合,计算混合移植物的免疫细胞组成;用MTT法和夹心ELISA法测定T细胞增殖能力和IL-4、IFN-γ的分泌。结果3种G-PB/G-BM混合移植物的T细胞增殖能力均低于未动员骨髓(NG-BM)和G-PB(P<0.05)。3种混合移植物与NG-BM、G-BM和G-PB在淋巴细胞、CD3 、CD4 、CD8 T细胞组成上存在差别(P<0.05);3种混合移植物的CD4/CD8比例都高于NG-BM和G-BM(P<0.01),DC1/DC2比值均低于NG-BM(P<0.01),IL-4/IFN-γ的比值均低于G-BM(P<0.05)。在输入相同CD34 细胞以保证植入的前提下,应用3种混合移植物进行移植时输入的Ⅰ型因子及Ⅰ型(Th1/Tc1)和Ⅱ型(Th2/Tc2)T细胞的数量介于NG-BM、G-BM和G-PB之间。结论G-PB/G-BM混合后免疫特性的改变可能在HLA不合移植中发挥作用。     

重组人粒细胞集落刺激因子对肝硬化大鼠外周血干细胞动员的研究

[目的]观察重组人粒细胞集落刺激因子(rhG-CSF)对四氯化碳(CCL4)肝硬化大鼠外周血中CD34+细胞的动员作用,以及对肝硬化大鼠肝脏生化学的影响,寻求一种安全有效、不加重肝损伤的动员CD34+细胞的方法。[方法]50%CCL4橄榄油溶液建立肝硬化大鼠模型,rhG-CSF动员组大鼠皮下注射rhG-CSF10μg.kg-1.d-1,共计5d,对照组给予相同剂量生理盐水。流式细胞仪测定外周血单个核细胞中的CD34+细胞的比例,同时检测ALT、AST、T-BIL和ALB,观察G-CSF对肝硬化大鼠肝脏的影响。[结果]肝硬化大鼠rhG-CSF动员后外周血CD34+细胞占单个核细胞(CD34+/MNC)比例(4.08±1.38)%是生理盐水对照组(0.43±0.21)%的9.5倍;而生化学检测两组没有显著性差异。[结论]G-CSF动员能促进更多的骨髓/造血干细胞源性的肝干细胞在外周血中表达,而且不加重肝硬化大鼠的肝脏损伤。     

粒细胞集落刺激因子对CD34+骨髓干细胞在心肌内归巢的影响

目的:观察粒细胞集落刺激因子(G-CSF)对CD34+骨髓干细胞(BMSC)在心肌内归巢的影响. 方法:成龄杂种犬17只,随机分4组. A组5只:接受10 μg/(kg·d),5 d皮下注射和实验性心梗;B组4只:接受10 μg/(kg·d),5 d皮下注射和假手术;C组4只:接受10 μg/(kg·d),5 d生理盐水皮下注射和实验性心梗;D组4只:接受10 μg/(kg·d),5 d生理盐水皮下注射和假手术,对每只动物股动脉插管至主动脉根部,左颈浅静脉插管至冠状静脉窦,分别于造型前后抽血5 mL(抽复管),裂解红细胞,分离单个核细胞,流式细胞仪测定CD34+细胞数,数据分析用SPSS 10.0统计软件包. 结果:4个实验组CD34+ BMSC心肌内归巢数分别为:(183.0±9.2)×104个/L,(71.1±9.2)×104个/L,(82.3±9.5)×103个/L和(78.5±9.8)×103/L,除C,D组之间差别无统计学意义(P=0.912)外,其余各组间均有统计学意义(均为P=0.000). 结论:G-CSF不仅能动员BMSC大量释放入外周血,同时还能增加CD34+ BMSC在心肌内的归巢.     

粒细胞集落刺激因子对大鼠颈总动脉损伤后新生内膜增生的影响

目的探讨粒细胞集落刺激因子（G-CSF）对动脉粥样硬化（AS）大鼠颈总动脉球囊损伤后再狭窄的影响。方法Wistar大鼠48只,随机分为3组:普通饮食组（普食组,n=6）,高脂饮食组（高脂组,n=42）。高脂组又分为:G-CSF组（n=21）和生理盐水组（NS组,n=21）。高脂饮食后1个月用HE染色及透射电镜证明AS形成情况。G-CSF组和NS组分别于高脂饮食后1个月给予G-CSF或生理盐水干预6d,然后行左颈总动脉球囊损伤术,术后14、21、90d分别用扫描电镜、HE染色及图像分析观察血管内皮形成及内膜的增生情况。结果高脂组大鼠高脂饮食后1个月可见AS的早期改变,行球囊损伤后可见大鼠颈总动脉内膜逐渐增厚,但是G-CSF组明显小于NS组,G-CSF组损伤血管内皮较快恢复连续性,G-CSF组内膜与中膜面积比值（Ai/Am）远小于NS组（P<0.01）。结论G-CSF可以加速AS大鼠损伤血管的再内皮化、抑制血管损伤后再狭窄的发生。     

The Gastrointestinal Tract Is an Alternative Route for SARS-CoV-2 Infection in a Nonhuman Primate Model

1. Download : Download high-res image (162KB)
2. Download : Download full-size image

     

Kimura 病1例并文献复习

目的 提高对少见疾病Kimura病的认识.方法 分析广州医学院第一附属医院广州呼吸疾病研究所于2008年7月29日收治的1例Kimura病伴支气管扩张患者的临床和病理资料,并复习相关文献.结果 患者,女,18岁,16年前接种卡介苗后反复咳嗽、咳痰、出现全身多发性包块,临床特征主要是血嗜酸性淋巴细胞增多、头颈部包块及淋巴结肿大和支气管扩张.颈部皮下肿物活检符合嗜酸性淋巴肉芽肿,对糖皮质激素治疗有效.结论 Kimura病属于少见病,合并支气管扩张是首例报道.